MedTrace Logo

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

NCT03624517 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-11-20

Study results available
· View outcomes & findings →

Summary

This study evaluates the safety and efficacy of 24-hour vs 72-hour octreotide infusion after variceal banding in cirrhotic patients with bleeding esophageal varices.

Conditions

  • Esophageal Varices
  • Liver Cirrhoses
  • Bleeding Esophageal Varices
  • Upper Gastrointestinal Bleeding

Interventions

DRUG

Octreotide

Octreotide infusion for 24-hours in patients with bleeding esophageal varices.

Sponsors & Collaborators

  • Ohio State University

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • University of Florida Health

    collaborator OTHER

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Don Rockey, M.D · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-19
Primary Completion
2024-12-01
Completion
2024-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03624517 on ClinicalTrials.gov